Why Shares of Myriad Genetics Dropped 24% This Week

What happened
Shares of Myriad Genetics (NASDAQ: MYGN), a genetic-testing and precision-medicine biotech company, were down more than 24% this week as of Thursday, according to data from S&P Global Intelligence. The stock closed last week at $20.86, then opened on Monday at $

admin